Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …

Therapeutics for patients hospitalized with coronavirus disease 2019 (COVID‐19) are
urgently needed during the pandemic. Bamlanivimab is a potent neutralizing monoclonal …

Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Abstract Background Coronavirus disease 2019 (COVID-19) has strained healthcare
systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies …

Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority.
Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal …

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly)
has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently …

The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …

Background Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically
efficacious when administered early, decreasing hospitalization and mortality in patients …

Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …